about
Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapyFOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancerReview of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice.Mechanisms and Targets Involved in Dissemination of Ovarian Cancer.Expression and clinicopathological implication of DcR3 in lung cancer tissues: a tissue microarray study with 365 casesPKG II reverses HGF-triggered cellular activities by phosphorylating serine 985 of c-Met in gastric cancer cells.MicroRNA-613 suppresses proliferation, migration and invasion of osteosarcoma by targeting c-MET.The selective c-Met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-Met activation in NSCLC models.The Multiple Roles of Exosomes in Metastasis.Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician.Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma.The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis.Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer.A clinically feasible multiplex proteomic immunoassay as a novel functional diagnostic for pancreatic ductal adenocarcinoma.Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma.Reviewing the Utility of EUS FNA to Advance Precision Medicine in Pancreatic Cancer.A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma.Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models.Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer.Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes.Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel.A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer
P2860
Q26741450-B3CEF4A7-27DE-4A37-9386-5542CFE59E89Q28075540-B5D53619-117A-4DC3-9087-AF6E186CC978Q33757138-6B32921C-DA5A-4655-8816-DAE868B5A5AFQ36180735-18AEE750-9EC7-49E3-9DCC-000A8CA704ADQ37179436-6CB9BD05-11F1-49AF-84C6-A53A4A0B8C98Q37376230-52E77A15-8254-4F94-AC19-520EBF2D9DE4Q37545114-0F29748C-BDFF-4318-9352-7F81008ADD70Q38704952-EA30AA57-2D6D-4FFF-B858-C30CE3999ADEQ39061503-F936AD60-DF12-4834-B69B-384C3C236615Q39233197-063A50DB-0198-4E1A-A9A6-F1C6226C677BQ39428273-0F6C811A-9EC4-46F8-AF85-AE6DAF8287CEQ41587809-E48E6AFA-5181-46AA-9E08-E65D3D42BF79Q41831075-1EB70176-210A-47C5-B98C-2FB31288D751Q42017784-BAF741CD-0B20-4518-8B79-9CAD139E3EF2Q47164059-06202DA3-96DB-4540-A4CF-200681E9AD1AQ47393972-B8443A34-2D98-4AC6-9675-24F5976896ACQ48140297-4BD5A1E3-ECAF-44EF-9A62-982CEBE9B8DAQ49576059-9AAFDB5E-E651-40FD-B667-2A437E679958Q49881127-9DAB22B1-8948-435B-86CC-E50F2F6D5FA0Q49887930-B96AAE97-4123-437B-88C6-6C443E8C6B1FQ50026654-5717A7E1-CB44-46BF-9152-FCA116966314Q50092066-A0ABD007-3120-49DB-87BC-84D919C20B3DQ50345931-F680033A-8D47-413E-9426-8CC5D2A76F6BQ55135232-AAA837B8-3E46-4A32-B451-353B8ADC2226Q57162835-C5F1F3E2-960D-40BF-A00C-5A85E5441ACF
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
c-Met as a Target for Personalized Therapy
@ast
c-Met as a Target for Personalized Therapy
@en
c-Met as a Target for Personalized Therapy
@nl
type
label
c-Met as a Target for Personalized Therapy
@ast
c-Met as a Target for Personalized Therapy
@en
c-Met as a Target for Personalized Therapy
@nl
prefLabel
c-Met as a Target for Personalized Therapy
@ast
c-Met as a Target for Personalized Therapy
@en
c-Met as a Target for Personalized Therapy
@nl
P2093
P2860
P3181
P356
P1476
c-Met as a Target for Personalized Therapy
@en
P2093
Elisa Giovannetti
Godefridus J Peters
Guido Biasco
Ingrid Garajová
P2860
P3181
P356
10.4137/TOG.S30534
P407
P433
P577
2015-01-01T00:00:00Z